Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 Env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide

Journal of Virology

Volumn 74, Issue 14, 2000, Pages 6278-6286

  Gherardi, M Magdalena ^a,c   Ramírez, Juan C ^a   Esteban, Mariano ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VIRUS ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DOSE RESPONSE; ENVELOPE GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV-1; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NITRIC OXIDE; SPLEEN; TH1 CELLS; TH2 CELLS; TIME FACTORS; VACCINES, DNA; VACCINIA VIRUS;

EID: 0343517098     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.14.6278-6286.2000     Document Type: Article

References (59)

1. Ahlers, J. D., N. Dunlop, D. W. Alling, P. L. Nara, and J. A. Berzofskv. 1997. Cytokine in adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J. Immunol. 158:3947-3958.
2. André, S., B. Seed, J. Eberle, W. Schraut, A. Bultman, and J. Haas. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72:1497-1503.
3. Andrew, M. E., B. E. H. Coupar, and D. B. Boyle. 1989. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol. Cell Biol. 67:331-337.
4. Bissinger, R. M., P. A. Tilbrook, P. G. Holt, and U. R. Kees. 1998. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signalling pathway. J. Immunol. 160:5729-5734.
5. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadianyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Rafaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:526-532.
6. Buseyne, F., M. Bugard, J. P. Teglas, E. Bui, C. Rouzioux, M. J. Mayaux, S. Blanche, and Y. Riviere. 1998. Early HIV-1-specific cytotoxic T lymphocytes and disease progression in children born to HIV-1-infected mothers. AIDS Res. Hum. Retrovir. 14:1435-1444.
7. Caver, T. E., T. D. Lockey, R. V. Srinivas, R. G. Webster, and J. L. Hurwitz. 1999. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 17:1567-1572.
8. Chow, Y. H., W. L. Huang, W. K. Chi, Y. D. Chu, and M. H. Tao. 1997. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:169-178.
9. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270:908.
10. Coughlin, C. M., M. Wysocka, G. Trinchieri, and W. M. F. Lee. 1997. The effect of interleukin-12 desensitization on the antitumor efficacy of recombinant interleukin-12. Cancer Res. 57:2460-2467.
11. Dallo, S., and M. Esteban. 1987. Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159:408-122.
12. Diefenbach, A., H. Schinndler, M. Röllinghoff, W. M. Yokohama, and C. Bogdan. 1999. Requirement of type 2 synthase for IL-12 signaling in innate immunity. Science 284:951-955.
13. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines Annu. Rev. Immunol. 15:617-648.
14. Duhé, R. J., G. A. Evans, R. A. Erwin, R. A. Kirken, G. W. Cox, and W. L. Farrar. 1998. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. USA 95:126-131.
15. Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson. 1993. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90: 11478-11482.
16. Gallimore, A., M. Cranage, N. Cook, N. Almond, J. Bootman, E. Rud, P. Silvera, M. Dennis, T. Corcoran, J. Stott, A. J. McMichael, and F. Gotch. 1995. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1:1167-1173.
17. Gherardi, M. M., and M. Esteban. 1999. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17:1074-1083.
18. Gherardi, M. M., J. C. Ramírez. D. Rodriguez, J. R. Rodriguez, G. Ichio, F. Zabala, and M. Esteban. 1999. IL-12 delivery from recombinant vaccinia virus attenuates vector infectivity and enhances cellular immune response against HIV-1 gp160 protein in a dose-dependent manner. J. Immunol. 162:6724-6733.
19. Goulder, P. J. R., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 3:212-217.
20. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Keeker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1988. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/ MVA boost vaccination regime. Vaccine 16:439-445.
21. Hanke, T., T. J. Blanchard, J. Schneider, G. S. Ogg, H. Tan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. J. McMichael. 1998. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for HIV-1 in mice. J. Gen. Virol. 79:83-90.
22. Hanke, T., and A. McMichael. 1999. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66:177-181.
23. Hanke, T., R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, S. A. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, M. P. Cranage, and A. J. McMichael. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
24. Harris, N., R. M. L. Buller, and G. Karupiah. 1995. Gamma interferon-induced nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:910-915.
25. Huang, F.-P., W. Niedbala, X. Q. Wei, X. Damo, G. Feng, J. H. Robinson, C. Lam, and F. Y. Liew. 1998. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur. J. Immunol. 28:4062-4070.
26. Karupiah, G., Q. W. Xie, R. M. L. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by Interferon-γ induced nitric oxide synthase. Science 261:1445-1448.
27. Kent, S. J., A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:10180-10188.
28. Kim, J. J., V. Ayavoo, M. L. Bargarazzi, M. A. Chattergoon, K. Dang, B. Wang, J. D. Boyer, and D. B. Weiner. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol. 158:816-826.
29. Kim, J. J., L. K. Nottingham, D. M. Wilson, M. L. Bagarazzi, A. Tsai, L. D. Morrison, A. Javadian, A. A. Chalian, M. G. Agadjanyan, and D. B. Weiner. 1998. Engineering DNA vaccines via co-delivery of stimulatory molecules genes. Vaccine 16:1828-1835.
30. Kim, J. J., N. N. Triveldi, L. K. Nottingham, L. Morrison, A. Tsai, V. Hu, S. Mahalingham, K. Dang, L. Ahn, N. K. Doyle, D. M. Wilson, M. A. Catterrgoon, A. A. Chalian, J. D. Boyer, M. G. Agadjanyan, and D. B. Weiner. 1998. Modulation of amplitude and direction of in vivo immune responses by coadministration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28:1089-1103.
31. Kremer, L., L. Dupré, Y. Wolowczuk, and C. Locht. 1999. In vivo immunomodulation following intradermal injection with DNA encoding IL-18. J. Immunol. 163:3226-3231.
32. Kündig, T. M., C. P. Kalberger, H. Hengartner, and R. M. Zinkernagel. 1993. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 111:1154-1158.
33. Kurzawa, H., C. A. Hunter, M. Wysocka, G. Trinchieri, and W. M. F. Lee. 1998. Immune suppression by recombinant IL-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant. J. Exp. Med. 188:1603-1610.
34. Kurzawa, H., M. Wysocka, E. Aruga, A. E. Chang, G. Trinchieri, and W. M. F. Lee. 1998. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res. 58:491-499.
35. Lasarte, J. J., F. J. Corrales, N. Casares, A. Lopez-Diaz de Cerio, C. Qian, X. Xie, K. Borrás-Cuesta, and J. Prieto. 1999. Different dose of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J. Immunol. 162:5270-5277.
36. Melková, Z., and M. Esteban. 1995. Inhibition of Vaccinia virus DNA replication by inducible expression of nitric oxid synthase. J. Immunol. 155: 5711-5718.
37. Miyahira, Y., A. García-Sastre, D. Rodríguez, J. R. Rodríguez, K. Murata, M. Tsuji, P. Palese, M. Esteban, F. Zavala, and R. S. Nussenzweig. 1998. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc. Natl. Acad. Sci. USA 95:3954-3959.
38. Okada, E., S. Sasaki, N. Ishii, Y. Aoki, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda. 1997. Intranasal immunization of a DNA vaccine with IL-12 and GM-CSF expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:3638-3647.
39. Pinto, L. A., J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Llanday, and G. M. Shearer. 1995. Env-specific cytotoxic T lymphocyte responses in HIV-1 seronegative health care workers occupationally exposed to HIV-1-contaminated body fluids. J. Clin. Investig. 96:867-876.
40. Price, D. A., A. K. Sewell, T. Dong, R. Tan, P. J. Goulder, S. L. Rowland-Jones, and R. E. Phillips. 1998. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr. Biol. 8:355-358.
41. Ramírez, J. C., M. M. Gherardi, and M. Esteban. 2000. The biology of attenuated modified vaccinia virus Ankara (MVA) recombinant vector in mice: fate and activation of B and T cell immune responses in comparison with the Western Reserve (WR) strain and advantages as a vaccine. J. Virol. 74:423-433.
42. Reiss, C. S., and T. Komatsu. 1998. Does nitric oxide play a critical role in viral infections? J. Virol. 72:4547-4551.
43. Robinson, H. L., D. Montefiori, P. Johnson, K. H. Manson, M. L. Kalish, J. Lifson, T. A. Rizvi, S. Lu, S. Hu, G. Mazzara, D. L. Panicali, J. G. Herndon, R. Glickman, M. A. Candido, S. Lydy, M. S. Wyand, and H. M. McClure. 1999. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant Pox virus booster immunizations. Nat. Med. 5:526-534.
44. Rodríguez, J. F., D. Rodríguez, J. R. Rodríguez, E. B. McGowan, and M. Esteban. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA 85:1667-1671.
45. Rolph, M. S., I. A. Ramshaw, K. A. Rotkett, J. Ruby, and W. B. Cowden. 1996. Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. Virology 217:470-477.
46. Rowland-Jones, S. L., T. Dong, K. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyosi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummber. 1998. Cytotoxic T cell responses to multiple conserved HIV-1 epitopes in HIV-1-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
47. Rowland-Jones, S. L., D. F. Nixon, M. C. Aldhous, F. Gotch, K. Ariyoshi, N. Hallam, J. S. Kroll, K. Froebel, and A. J. McMichael. 1993. HIV-1-specific cytotoxic T-cell activity in an HIV-1-exposed but uninfected infant. Lancet 341:860-861.
48. Rowland-Jones, S. L., H. Tan, and A. J. McMichael. 1997. The role of cellular immunity in protection against HIV-1 infection. Adv. Immunol. 65:277-346.
49. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and S. L. Hoffman. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95:7648-7653.
50. Schmitz, J. E., M. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalessandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in SIV infection by CD8+ lymphocytes. Science 283:857-860.
51. Schneider, J., S. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. S. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
52. Sin, J. I., J. H. Sung, V. S. Suh, A. H. Lee, J. H. Chung, and Y. C. Sung. 1997. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocytemacrophage colony stimulation factor gene. Vaccine 15:1827-1833.
53. Takashi, T., K. Hamajima, J. Fukushima, K. Q. Xin, N. Ishii, I. Aoki, V. Ishigatsubo, K. Tani, S. Kawamoto, Y. Nitta, J. Miyazaki, W. C. Kokk, T. Okubo, and K. Okuda. 1997. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid encoded HIV-1 antigen with plasmid expressing IL-12. J. Immunol. 158:4008-4013.
54. Tarrant, T. K., P. B. Silver, J. L. Wahltesn, L. V. Rizzo, C. C. Chan, B. Wiggert, and R. R. Caspi. 1999. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon γ, nitric oxide, and apoptosis. J. Exp. Med. 189:219-230.
55. Trinchieri, G. 1994. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008-4027.
56. Wagner, L., O. O. Yang, E. A. García-Zepeda, Y. Ge, S. A. Kalams, B. D. Walker, M. S. Pasternack, and A. D. Luster. 1998. Beta-chemokines are released from HIV-1 specific cytolitic T cell granules complexed to proteglycans. Nature 391:908-911.
57. Xiang, Z., and H. C. J. Ertl. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129-135.
58. Xin, K. Q., K. Hamajima, S. Sasaki, T. Tsuji, S. Watabe, E. Okada, and K. Okuda. 1999. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17:858-866.
59. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolitic mechanisms. J. Virol. 71:3120-3128.